Come see what I-SPY has been up to at the 2018 San Antonio Breast Cancer Symposium
Dynavax Technologies Corporation and Quantum Leap Healthcare Collaborative™ announced that Dynavax’s SD-101 and KEYTRUDA® (pembrolizumab) will be evaluated in the I-SPY 2 TRIAL
A combination of poly (ADP-ribose) polymerase (PARP) enzyme inhibitor olaparib and anti-PD-L1 monoclonal antibody immunotherapy agent durvalumab, both from AstraZeneca, will be evaluated in I-SPY 2.
OncLive® announced Dr. Laura Esserman as an inductee of the 2018 Giants of Cancer Care® recognition program.
Data Presented at San Antonio Breast Cancer Symposium Show Significant and Clinically Impactful Relationship Between pCR and Event-Free Survival in High-Risk Breast Cancer.
New Data Analyses Presented at San Antonio Breast Cancer Symposium Spotlight Predictive Response to Pembrolizumab and MK-2206, and Demonstrate Improved Predictive Performance of Breast MRI
With this new technology, the I-SPY 2 TRIAL can better help match agents, combinations, and additional targeted interventions to women with high-risk breast cancers.